The Food and Drug Administration evaluates drugs for safety and effectiveness, but now the Centers for Medicare and Medicaid Services want to act as political scrutiny of FDA decisions. Last week, CMS refused to cover a novel Alzheimer’s treatment for millions of patients because it disagreed with FDA approval.
Biogen’s Aduhelm is the first FDA-approved treatment shown to slow the progression of Alzheimer’s disease. But the drug is now embroiled in a political battle. The public health left thinks the FDA is approving too many new expensive drugs with little benefit and wants CMS to overrule the drug agency. Progressives are hailing CMS Aduhelm’s decision as a precedent for the agency to restrict access to new FDA-approved treatments. Aduhelm is the target today, but cancer and gene therapies could be next.
https://www.wsj.com/articles/bidens-bureaucracy-and-alzheimers-drug-fda-cms-aduhelm-biogen-treatment-medicare-11649714296 Sandbagging an Alzheimer’s Treatment – WSJ